We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

C4X Discovery Holdings plc (C4XD) Ordinary Shares 1p

Sell:11.40p Buy:12.65p 0 Change: No change
Market closed Prices as at close on 4 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.40p
Buy:12.65p
Change: No change
Market closed Prices as at close on 4 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.40p
Buy:12.65p
Change: No change
Market closed Prices as at close on 4 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Company’s pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.

Contact details

Address:
Manchester One, 53 Portland Street
MANCHESTER
M1 3LD
United Kingdom
Telephone:
+44 (0161) 2355085
Website:
https://www.c4xdiscovery.com/

Important dates

Future events
There are no future events available.
Past events
AGM 23 January 2024 23/01/24
Annual report 18 December 2023 18/12/23
Final results 14 December 2023 14/12/23

General stock information

EPIC:
C4XD
ISIN:
GB00BQQ2RV18
Market cap:
£29.01 million
Shares in issue:
252.23 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Brad Hoy
    Chief Financial Officer, Executive Director, Company Secretary
  • Clare Murray
    Senior Vice President - Drug Discovery
  • Nick Ray
    Chief Scientific Officer
  • Bhavna Hunja
    Executive Director, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.